{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:15:23Z","timestamp":1794352523469,"version":"4.9.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:45:53Z","timestamp":1778571953000},"page":"343-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer: Molecular mechanisms and therapeutic strategies"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3614-9679","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2026.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/febs.16657","article-title":"Repression of slc22a3 by the ar-v7\/yap1\/taz axis in enzalutamide-resistant castration-resistant prostate cancer","volume":"290","author":"Seo","year":"2023","journal-title":"FEBS J"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-04162-0","article-title":"Selective degradation of ar-v7 to overcome castration resistance of prostate cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41568-024-00772-w","article-title":"Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities","volume":"25","author":"Dotto","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0004","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41388-022-02179-z","article-title":"Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by pkc\u03b21","volume":"41","author":"Melnyk","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116400","article-title":"Novel selective agents for the degradation of ar\/ar-v7 to treat advanced prostate cancer","volume":"271","author":"Yang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.011_bib0006","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1021\/acs.jmedchem.3c02177","article-title":"Structure-activity relationship (sar) studies of novel monovalent ar\/ar-v7 dual degraders with potent efficacy against advanced prostate cancer","volume":"67","author":"Xiao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2022.09.032","article-title":"Caba-v7: a prospective biomarker selected trial of cabazitaxel treatment in ar-v7 positive prostate cancer patients","volume":"177","author":"Isebia","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117079","article-title":"Discovery of a highly potent, n-terminal domain-targeting degrader of ar-fl\/ar-v7 for the treatment of prostate cancer","volume":"282","author":"Ha","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0009","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"Ar-v7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.urolonc.2026.04.011_bib0010","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/cancers14194877","article-title":"The crucial role of ar-v7 in enzalutamide-resistance of castration-resistant prostate cancer","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01067-3","article-title":"Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world aron-3 study","author":"B\u00fcttner","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0012","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world aron-3 study","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0013","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of ar-v7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.urolonc.2026.04.011_bib0015","doi-asserted-by":"crossref","first-page":"20512","DOI":"10.1021\/jacs.5c02801","article-title":"Covalent destabilizing degrader of ar and ar-v7 in androgen-independent prostate cancer cells","volume":"147","author":"Zammit","year":"2025","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad048","article-title":"The transmembrane protein tm4sf3 interacts with ar and ar-v7 and is recruited to ar target genes","volume":"164","author":"Khatiwada","year":"2023","journal-title":"Endocrinology"},{"issue":"20","key":"10.1016\/j.urolonc.2026.04.011_bib0017","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41388-024-02944-2","article-title":"Sc912 inhibits ar-v7 activity in castration-resistant prostate cancer by targeting the androgen receptor n-terminal domain","volume":"43","author":"Yi","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12964-022-00925-0","article-title":"Androgen receptor variant-7 regulation by tenascin-c induced src activation","volume":"20","author":"Thomas","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/0008-5472.CAN-24-0591","article-title":"An autophagy-targeting chimera induces degradation of androgen receptor mutants and ar-v7 in castration-resistant prostate cancer","volume":"85","author":"Bae","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12967-025-06115-z","article-title":"A novel peptide encoded by circsrcap confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of ar-v7 in castration-resistant prostate cancer","volume":"23","author":"Meng","year":"2025","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115089","article-title":"Increased nuclear factor i-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer","volume":"44","author":"Poluben","year":"2025","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0022","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","article-title":"Jmjd6 is a druggable oxygenase that regulates ar-v7 expression in prostate cancer","volume":"81","author":"Paschalis","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","article-title":"Lncrna hotair enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Rep"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.011_bib0024","doi-asserted-by":"crossref","first-page":"17694","DOI":"10.18632\/aging.103917","article-title":"Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-na\u00efve prostate cancer cells","volume":"12","author":"Lin","year":"2020","journal-title":"Aging"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.011_bib0025","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0026","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73396","article-title":"Ar-v7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer","volume":"11","author":"Kim","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40364-023-00481-w","article-title":"Co-expression and clinical utility of ar-fl and ar splice variants ar-v3, ar-v7 and ar-v9 in prostate cancer","volume":"11","author":"W\u00fcstmann","year":"2023","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.011_bib0028","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41388-020-01585-5","article-title":"A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells","volume":"40","author":"Roggero","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0029","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.biocel.2012.12.012","article-title":"Targeted disruption of the p160 coactivator interface of androgen receptor (ar) selectively inhibits ar activity in both androgen-dependent and castration-resistant ar-expressing prostate cancer cells","volume":"45","author":"Nakka","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free dna and splicing variant 7 in exosomes predict clinical outcome in crpc patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0031","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/jcm7110444","article-title":"Androgen receptor splice variant 7 drives the growth of castration resistant prostate cancer without being involved in the efficacy of taxane chemotherapy","volume":"7","author":"Shimizu","year":"2018","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Investig"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.011_bib0033","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41419-021-04144-2","article-title":"Lncrna pcbp1-as1-mediated ar\/ar-v7 deubiquitination enhances prostate cancer enzalutamide resistance","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108743","article-title":"Nutraceuticals target androgen receptor-splice variants (ar-sv) to manage castration resistant prostate cancer (crpc)","volume":"264","author":"Tyagi","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.urolonc.2026.04.011_bib0035","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-22-0851","article-title":"Assessment of androgen receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer","volume":"28","author":"Sowalsky","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0036","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","article-title":"Kif15-mediated stabilization of ar and ar-v7 contributes to enzalutamide resistance in prostate cancer","volume":"81","author":"Gao","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0037","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/0008-5472.CAN-20-3845","article-title":"Loss of long noncoding rna nxtar in prostate cancer augments androgen receptor expression and enzalutamide resistance","volume":"82","author":"Ghildiyal","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0038","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-024-07413-w","article-title":"Identification of selective swi\/snf dependencies in enzalutamide-resistant prostate cancer","volume":"8","author":"Gokbayrak","year":"2025","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0039","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cells13010104","article-title":"Therapeutic approaches to targeting androgen receptor splice variants","volume":"13","author":"Daniels","year":"2024","journal-title":"Cells"},{"issue":"31","key":"10.1016\/j.urolonc.2026.04.011_bib0040","doi-asserted-by":"crossref","first-page":"31997","DOI":"10.18632\/oncotarget.5585","article-title":"Differential regulation of metabolic pathways by androgen receptor (ar) and its constitutively active splice variant, ar-v7, in prostate cancer cells","volume":"6","author":"Shafi","year":"2015","journal-title":"Oncotarget"},{"issue":"30","key":"10.1016\/j.urolonc.2026.04.011_bib0041","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41388-023-02756-w","article-title":"Critical role of antioxidant programs in enzalutamide-resistant prostate cancer","volume":"42","author":"Blatt","year":"2023","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.011_bib0042","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/biomedicines13051182","article-title":"Normal weight, overweight and obesity conditions associated to prostate neoplasm stages-a systematic review and meta-analysis","volume":"13","author":"Vitale","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0043","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2021.10.042","article-title":"Enzalutamide-induced and pth1r-mediated tgfbr2 degradation in osteoblasts confers resistance in prostate cancer bone metastases","volume":"525","author":"Su","year":"2022","journal-title":"Cancer Lett"},{"issue":"14","key":"10.1016\/j.urolonc.2026.04.011_bib0044","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-20-3471","article-title":"Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mcrpc treated with abiraterone or enzalutamide","volume":"27","author":"Brown","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.011_bib0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0046","doi-asserted-by":"crossref","first-page":"e7386","DOI":"10.1136\/jitc-2023-007386","article-title":"Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to nk-mediated lysis","volume":"11","author":"Dahut","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"16","key":"10.1016\/j.urolonc.2026.04.011_bib0047","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/0008-5472.CAN-21-0198","article-title":"Bidirectional cross-talk between maoa and ar promotes hormone-dependent and castration-resistant prostate cancer","volume":"81","author":"Wei","year":"2021","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112798","article-title":"Spermine is a natural suppressor of ar signaling in castration-resistant prostate cancer","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110417","article-title":"A genome-scale crispr screen reveals prmt1 as a critical regulator of androgen receptor signaling in prostate cancer","volume":"38","author":"Tang","year":"2022","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0050","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.7150\/thno.42345","article-title":"Prmt1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0051","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41419-022-04787-9","article-title":"Rnf8 up-regulates ar\/arv7 action to contribute to advanced prostate cancer progression","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0052","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1158\/1535-7163.MCT-20-0244","article-title":"Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro","volume":"20","author":"Kohrt","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.urolonc.2026.04.011_bib0053","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","article-title":"Discovery of small-molecule degraders of the cdk9-cyclin t1 complex for targeting transcriptional addiction in prostate cancer","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"issue":"35","key":"10.1016\/j.urolonc.2026.04.011_bib0054","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1038\/s41388-021-01914-2","article-title":"Arvib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0055","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s42003-021-02321-9","article-title":"Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage","volume":"4","author":"Gjyrezi","year":"2021","journal-title":"Commun Biol"},{"issue":"878","key":"10.1016\/j.urolonc.2026.04.011_bib0056","doi-asserted-by":"crossref","first-page":"eadi5174","DOI":"10.1126\/scisignal.adi5174","article-title":"The kinase plk1 promotes hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer","volume":"18","author":"Zhang","year":"2025","journal-title":"Sci Signal"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0057","article-title":"Huaier extract inhibits prostate cancer growth via targeting ar\/ar-v7 pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0058","doi-asserted-by":"crossref","first-page":"958","DOI":"10.7150\/thno.51478","article-title":"Bruceantin targets hsp90 to overcome resistance to hormone therapy in castration-resistant prostate cancer","volume":"11","author":"Moon","year":"2021","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115487","article-title":"Hypoxia-induced prmt1 methylates hif2\u03b2 to promote breast tumorigenesis via enhancing glycolytic gene transcription","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/2159-8290.CD-21-0184","article-title":"Toppling the hat to treat lethal prostate cancer","volume":"11","author":"Rasool","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117407","article-title":"Handheld isfet lab-on-chip detection of yap1 nucleic acid and ar-fl and ar-v7 mrna from liquid biopsies for prostate cancer prognosis","volume":"281","author":"Broomfield","year":"2025","journal-title":"Biosens Bioelectron"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0062","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/1078-0432.CCR-23-3083","article-title":"Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in different stages of prostate cancer","volume":"30","author":"Cho","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0063","doi-asserted-by":"crossref","first-page":"e1028","DOI":"10.1002\/ctm2.1028","article-title":"Positive epigenetic regulation loop between ar and nsun2 promotes prostate cancer progression","volume":"12","author":"Zhu","year":"2022","journal-title":"Clin Transl Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0064","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41388-022-02566-6","article-title":"Novel inhibition of akr1c3 and androgen receptor axis by ptupb synergizes enzalutamide treatment in advanced prostate cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Oncogene"},{"issue":"Pt 1","key":"10.1016\/j.urolonc.2026.04.011_bib0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.semcancer.2021.08.004","article-title":"Exosomes and prostate cancer management","volume":"86","author":"Vlaeminck-Guillem","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.011_bib0066","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1021\/acssensors.1c02551","article-title":"Application of surface-enhanced Raman spectroscopy to guide therapy for advanced prostate cancer patients","volume":"7","author":"Rajput","year":"2022","journal-title":"ACS Sens"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0067","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.ymthe.2023.09.011","article-title":"Targeting prmt1 prevents acute and chronic graft-versus-host disease","volume":"31","author":"Zhao","year":"2023","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.urolonc.2026.04.011_bib0068","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41419-024-06898-x","article-title":"Prmt1 promotes warburg effect by regulating the pkm2\/pkm1 ratio in non-small cell lung cancer","volume":"15","author":"Peng","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0069","first-page":"1","article-title":"Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy","author":"Konieczkowski","year":"2025","journal-title":"NPJ Precis Oncol 10 (1)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-24-1658","article-title":"Genomic and epigenomic analysis of plasma cell-free dna identifies stemness features associated with worse survival in lethal prostate cancer","volume":"31","author":"Chauhan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.urolonc.2026.04.011_bib0071","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-23-2260","article-title":"The critical interplay of caf plasticity and resistance in prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116338","article-title":"Androgen receptor cofactors: a potential role in understanding prostate cancer","volume":"173","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0073","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.apsb.2023.05.026","article-title":"Predicting and overcoming resistance to cdk9 inhibitors for cancer therapy","volume":"13","author":"Hu","year":"2023","journal-title":"Acta Pharma Sin B"},{"issue":"22","key":"10.1016\/j.urolonc.2026.04.011_bib0074","doi-asserted-by":"crossref","first-page":"15340","DOI":"10.1021\/acs.jmedchem.3c01400","article-title":"Discovery of selective and potent macrocyclic cdk9 inhibitors for the treatment of osimertinib-resistant non-small-cell lung cancer","volume":"66","author":"Wu","year":"2023","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.011_bib0075","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jid.2020.12.035","article-title":"The molecular context of vulnerability for cdk9 suppression in triple wild-type melanoma","volume":"141","author":"Guhan","year":"2021","journal-title":"J Investig Dermatol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.011_bib0076","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1097\/JS9.0000000000002611","article-title":"Prostate cancer stem cell dynamics in the evolution of drug resistance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"issue":"21","key":"10.1016\/j.urolonc.2026.04.011_bib0077","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"Lx1 dual targets ar variants and akr1c3 in advanced prostate cancer therapy","volume":"84","author":"Ning","year":"2024","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.011_bib0078","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.jaci.2020.12.646","article-title":"Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines","volume":"147","author":"Park","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0079","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/path.5652","article-title":"Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer","volume":"254","author":"Porter","year":"2021","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymthe.2022.08.019","article-title":"Antagonizing cd105 and androgen receptor to target stromal-epithelial interactions for clinical benefit","volume":"31","author":"Smith","year":"2023","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.011_bib0081","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17425255.2022.2072727","article-title":"Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving parp inhibitors: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0082","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s43556-025-00354-8","article-title":"Histone methyltransferase kmt2d targets the spop-g3bp1 axis to enhance ar stability and drive castration-resistant prostate cancer progression","volume":"6","author":"Wen","year":"2025","journal-title":"Mol Biomed"},{"issue":"26","key":"10.1016\/j.urolonc.2026.04.011_bib0083","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0084","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1038\/s41467-022-35135-2","article-title":"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential","volume":"13","author":"Kneppers","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0085","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1038\/s41467-022-33069-3","article-title":"Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones","volume":"13","author":"Marklund","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0086","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0087","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163498","article-title":"Bmx controls 3\u03b2hsd1 and sex steroid biosynthesis in cancer","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.011_bib0088","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"Vip152 is a selective cdk9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.urolonc.2026.04.011_bib0089","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41419-022-05366-8","article-title":"Androgen deprivation restores arhgef2 to promote neuroendocrine differentiation of prostate cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"18","key":"10.1016\/j.urolonc.2026.04.011_bib0090","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","article-title":"An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression","volume":"84","author":"Shrestha","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0091","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41467-021-25623-2","article-title":"Transcriptional network involving erg and ar orchestrates distal-less homeobox-1 mediated prostate cancer progression","volume":"12","author":"Goel","year":"2021","journal-title":"Nat Commun"},{"issue":"33","key":"10.1016\/j.urolonc.2026.04.011_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400398","article-title":"Ubx-390: a novel androgen receptor degrader for therapeutic intervention in prostate cancer","volume":"11","author":"Lee","year":"2024","journal-title":"Adv Sci"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.011_bib0093","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/clinchem\/hvac125","article-title":"Development and analytical validation of a 6-plex reverse transcription droplet digital pcr assay for the absolute quantification of prostate cancer biomarkers in circulating tumor cells of patients with metastatic castration-resistant prostate cancer","volume":"68","author":"Zavridou","year":"2022","journal-title":"Clin Chem"},{"issue":"9\u201310","key":"10.1016\/j.urolonc.2026.04.011_bib0094","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s10495-024-01941-w","article-title":"Loss of ar-regulated aff3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating acsl4 based on single-cell sequencing analysis","volume":"29","author":"Fan","year":"2024","journal-title":"Apoptosis"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0095","doi-asserted-by":"crossref","unstructured":"Y Ju, J Watson, JJ Wang, et al. B7-h3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer. Drug Resist Updates 79 (2025) 101207. https:\/\/doi.org\/10.1016\/j.drup.2025.101207.","DOI":"10.1016\/j.drup.2025.101207"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.011_bib0096","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2025.03.017","article-title":"Reprogramming of androgen receptor activity in castration-resistant prostate cancer is shaped by truncated variants","volume":"11","author":"Lawrence","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0097","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.011_bib0098","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu0847","article-title":"Acute brcaness induction and ar pathway blockage through cdk12\/7\/9 degradation enhances parp inhibitor sensitivity in prostate cancer","volume":"11","author":"Gui","year":"2025","journal-title":"Sci Adv"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.011_bib0099","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1158\/1078-0432.CCR-25-2121","article-title":"Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer","volume":"31","author":"Brighi","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114112","article-title":"Targeting androgen receptor degradation with protacs from bench to bedside","volume":"158","author":"Jia","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.011_bib0101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41389-023-00449-3","article-title":"Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-myc-driven mouse hcc model","volume":"12","author":"Kido","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.urolonc.2026.04.011_bib0102","article-title":"Oral bioavailable itri-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer","volume":"71","author":"Hung","year":"2025","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (arv-110), a novel proteolysis targeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.011_bib0104","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1021\/acs.jctc.5c00171","article-title":"Small molecules targeting the structural dynamics of ar-v7 partially disordered proteins using deep ensemble docking","volume":"21","author":"Karatzas","year":"2025","journal-title":"J Chem Theory Comput"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.011_bib0105","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112184","article-title":"Yap antagonizes tead-mediated ar signaling and prostate cancer growth","volume":"42","author":"Li","year":"2023","journal-title":"EMBO J"},{"issue":"15","key":"10.1016\/j.urolonc.2026.04.011_bib0106","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41388-024-03266-z","article-title":"Oncogenic potential of truncated-gli3 via the gsk3\u03b2\/gli3\/ar-v7 axis in castration-resistant prostate cancer","volume":"44","author":"Kaushal","year":"2025","journal-title":"Oncogene"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600219X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600219X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:04:58Z","timestamp":1780920298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600219X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S107814392600219X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer: Molecular mechanisms and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}